Magforce Nanotechnologies Releases Clinical Data on Magnetic Iron-Oxide Nanoparticles in Patients with Recurrent Glioblastoma Multiforme

MagForce Nanotechnologies AG (FSE:MF6) announced today the publication of clinical data from a clinical study examining the safety and efficacy of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy in patients with recurrent glioblastoma multiforme.

The study data, published on September 20, 2010 in the Journal of Neuro-Oncology, is available online on the Journal's website at

"This data publication provides detailed insight into the clinical data that supported our recent regulatory approval for Nano-CancerÒ therapy. Through the publication, we are pleased to address a wider international audience and give them insight into MagForce's novel concept of using nanotechnology for the treatment of cancer," said Dr. Peter Heinrich, CEO of MagForce Nanotechnologies AG. "We are currently focused on strengthening our commercialization team and infrastructures in preparation for the next strategic steps, including the planned Q1 2011 product launch in Germany, additional clinical trials, and further internationalization."

Nano-Cancer therapy uses iron oxide nanoparticles, which are injected into the tumor and, due to their special coating, aggregate and remain in place. The patient is then placed into a magnetic field applicator. Through the application of an alternating magnetic field, the nanoparticles begin to oscillate, produce warmth, and damage or kill the tumor tissue.

MagForce Nanotechnologies AG is a leader in the area of nanotechnology-based cancer treatment. The proprietary procedure which it has developed, Nano-Cancer therapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from magnetic nanoparticles. Its products used in the therapy, NanoTherm and NanoActivator, have received EU-wide regulatory approval as medical devices for the treatment of brain tumors.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    MagForce Nanotechnologies AG. (2019, February 13). Magforce Nanotechnologies Releases Clinical Data on Magnetic Iron-Oxide Nanoparticles in Patients with Recurrent Glioblastoma Multiforme. AZoNano. Retrieved on April 23, 2024 from https://www.azonano.com/news.aspx?newsID=19611.

  • MLA

    MagForce Nanotechnologies AG. "Magforce Nanotechnologies Releases Clinical Data on Magnetic Iron-Oxide Nanoparticles in Patients with Recurrent Glioblastoma Multiforme". AZoNano. 23 April 2024. <https://www.azonano.com/news.aspx?newsID=19611>.

  • Chicago

    MagForce Nanotechnologies AG. "Magforce Nanotechnologies Releases Clinical Data on Magnetic Iron-Oxide Nanoparticles in Patients with Recurrent Glioblastoma Multiforme". AZoNano. https://www.azonano.com/news.aspx?newsID=19611. (accessed April 23, 2024).

  • Harvard

    MagForce Nanotechnologies AG. 2019. Magforce Nanotechnologies Releases Clinical Data on Magnetic Iron-Oxide Nanoparticles in Patients with Recurrent Glioblastoma Multiforme. AZoNano, viewed 23 April 2024, https://www.azonano.com/news.aspx?newsID=19611.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.